Advisors

Medical and Scientific Advisors

Nick_prdpf

Nicholas J. Licato, JD PhD

Dr. Licato holds a PhD in Medicinal Chemistry from the University of Utah and a JD from University of San Diego School of Law. Dr. Licato has over 25 years of experience in the pharmaceutical industry, including chemical (API) and product development, and more recently as a corporate counsel. Dr. Licato was also an analytical and environmental sciences instructor at UC Berkeley, and has served on various committees of the Food and Drug Law institute and the Natural Products Association. He was a securities and consumer class action attorney for over six years and has published and presented on litigation issues facing the pharma and dietary supplements industry, notably California’s Proposition 65. Admitted to the California State Bar in 2002, Dr. Licato is currently engaged in corporate, life sciences and FDA regulatory practice, as Vice President and General Counsel for Nexgen Pharma, Inc., a pharmaceuticals manufacturer headquartered in Irvine, California.

Michael G. Palfreyman

Michael G. Palfreyman, BPharm, Ph.D., DSc., MRPharmS

Past Companies: Marrion Merrell Dow, Amakem, Oculogics, and other companies.
Michael G. Palfreyman is a seasoned leader in the biotechnology and pharmaceutical industries with over 40 years’ experience in leadership positions.

Dr. Palfreyman is President, Palfreyman BioPharm Advisors, Inc.; Chairman of the Board, Amakem, NV (www.amakem.com) and Director, Oculogics, Inc (www.oculogics.com).  In addition, he is Head, R&D Diligence at Torrey Pines Investment (www.torreypinesinv.com)  and Senior R&D Diligence at ChemRar (www.chemrar.ru);  Head, Translational R&D at ChemDiv, Inc.(www.chemdiv.com)  as well as Senior Scientific Advisor for EnVivo Pharmaceuticals, Inc. (www.envivopharma.com), and Scientific Advisor to Avineuro,Inc. (www.avineuro.com), Aminex Therapeutics, (www.aminextherapeutics.com),  and NeuroNascent, Inc. (www.neuronascent.com).

Previously, Michael was VP, Program Management & Product Development at EnVivo Pharmaceuticals where he was responsible for the late stage discovery and preclinical development of two CNS drugs now demonstrating efficacy in Phase 2 clinical testing. As a co-founder NOVACE Corporation, Michael worked closely with Investors and Biotechnology Companies to bring products from discovery through to the value point of clinical validation.

Before joining NOVACE, Michael held a number of executive positions at Psychiatric Genomics, Scriptgen (Anadys) Pharmaceuticals as well as Marion Merrell Dow Research Institute (Sanofi-Aventis). In addition to overseeing research programs in Psychiatric, Neurological, Cardiovascular, Cancer, Infectious, Metabolic and Respiratory Disorders, Dr. Palfreyman’s own research included discovery and development of a number of psychotherapeutic compounds for treatment of psychosis, depression, stroke, epilepsy, emesis, Parkinson’s, Alzheimer’s and Huntington’s diseases. Many of these compounds have entered clinical development and a number have reached the marketplace. He has been an invited speaker and chairperson for a number of international and national conferences, is co-inventor on 35 issued US patents, 3 pending patents and co-author of over 150 scientific articles and book chapters.

krupp

Michael Krupp, Ph.D.

Dr. Krupp is a Business and Technology Adviser the von Liebig Center for Entrepreneurism and Technology advancement at the UCSD Jacobs School of Engineering focused on the Life Sciences area.  In addition, He also is currently the CEO of two startup companies, Neurgain Technologies and Xfibra, LLC, that are based on UC San Diego technologies.  Dr. Krupp is a member of the Board of the CONNECT Foundation.

Previously Dr. Krupp was Sr. V.P. of Business Development and Chief Business Officer of Chugai Pharma USA, LLC (CPUSA) in San Diego. Dr. Krupp was responsible for identifying and acquiring products and technology to complement and expand CPUSA’s project pipeline. He lead the market research and strategic marketing efforts for Chugai drug candidates outside of Japan including the recently approved anti-IL-6 receptor antibody, Actemira, a novel agent for the treatment of rheumatoid arthritis.  He was also responsible for general business operations.  Prior to Chugai, Dr. Krupp served as Director, Licensing and Development, at Pfizer, Inc. He started his industry career in Pfizer Central Research in the areas of Diabetes drug discovery and General Pharmacology.

Dr. Krupp received his B.S. in Chemistry from Hobart College and his Ph.D. in Biochemistry from the University of Rochester, School of Medicine.  He completed his Postdoctoral Research at The Johns Hopkins University School of Medicine.

Visit Us On FacebookVisit Us On TwitterVisit Us On PinterestVisit Us On YoutubeVisit Us On Linkedin